achn-975
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01597947)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
lpxC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(N)[C@H](NC(=O)c1ccc(C#CC#C[C@@H]2C[C@H]2CO)cc1)C(=O)NO- Mol. weight
- 369.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3939284 ↗
Also known as
- achn-975
- achn-975
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01870245 | Phase 1 | May 1, 2013 | Achaogen, Inc. |
| NCT01597947 | Phase 1 | May 1, 2012 | Achaogen, Inc., Defense Medical Research and Development Program |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Achaogen, Inc. | For profit | 2 | 2 | 1 | 2012 |
| Defense Medical Research and Development Program | Government | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1